CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Alemtuzumab 治疗血液系统恶性肿瘤
英文原题：Alemtuzumab for haematological malignancies.
查看英文原题
Alemtuzumab for haematological malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
阿仑单抗是一种人源化重组单克隆抗体，可特异性靶向CD52抗原；CD52同时表达于恶性及正常T、B淋巴细胞上。阿仑单抗结合CD52后可发挥强效抗肿瘤和免疫抑制作用。该药于2001年首次获美国食品药品监督管理局批准用于B细胞慢性淋巴细胞白血病（B-CLL），此后治疗应用扩展至多种血液系统恶性肿瘤及相关疾病，包括淋巴瘤、急性白血病、骨髓增生异常综合征（MDS）、再生障碍性贫血（AA）、移植物抗宿主病（GVHD）及CAR-T 细胞治疗。本综述评估阿仑单抗在这些疾病中的疗效和安全性，旨在汇总当前证据并为临床实践提供指导，以优化阿仑单抗的应用。
展开英文摘要原文
Alemtuzumab is a humanized recombinant monoclonal antibody that specifically targets the CD52 antigen, which is expressed on both malignant and normal T and B lymphocytes. By binding to CD52, alemtuzumab exerts potent antitumor and immunosuppressive effects.
Initially approved by the FDA in 2001 for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), alemtuzumab's therapeutic applications have expanded to various hematologic malignancies, including lymphoma, acute leukemia, myelodysplastic syndromes (MDS), aplastic anemia (AA), graft-versus-host disease (GVHD), and chimeric antigen receptor T-cell (CAR-T) therapy.
This review evaluates the efficacy and safety of alemtuzumab in these conditions, aiming to synthesize current evidence and provide guidance for clinical practice to optimize the use of alemtuzumab in the treatment of these diseases.
论文信息
- 作者
- An N、Bian K、Li C
- 第一作者单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, China.China
- 通讯作者单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, 430030, Hubei, China. cunrui5650@hust.edu.cn.China
- 文献类型
- 综述
- 期刊
- Annals of hematology2025 May
- 原文标识
- PubMed 40214729 · DOI 10.1007/s00277-025-06344-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →